IGM BIOSCIENCES INC (IGMS)
US4495851085 - Common Stock
We assign a fundamental rating of 3 out of 10 to IGMS. IGMS was compared to 568 industry peers in the Biotechnology industry. The financial health of IGMS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IGMS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year IGMS has reported negative net income.
IGMS had a negative operating cash flow in the past year.
IGMS had negative earnings in each of the past 5 years.
IGMS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
IGMS has a worse Return On Assets (-72.20%) than 67.08% of its industry peers.
With a Return On Equity value of -278.47%, IGMS is not doing good in the industry: 73.27% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.2% | ||
| ROE | -278.47% | ||
| ROIC | N/A |
ROA(3y)-52.22%
ROA(5y)-38.61%
ROE(3y)-88.55%
ROE(5y)-60.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IGMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IGMS has more shares outstanding
IGMS has more shares outstanding than it did 5 years ago.
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -5.04, we must say that IGMS is in the distress zone and has some risk of bankruptcy.
IGMS's Altman-Z score of -5.04 is on the low side compared to the rest of the industry. IGMS is outperformed by 61.95% of its industry peers.
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.04 |
ROIC/WACCN/A
WACC11.91%
2.3 Liquidity
IGMS has a Current Ratio of 5.22. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.22, IGMS perfoms like the industry average, outperforming 55.93% of the companies in the same industry.
A Quick Ratio of 5.22 indicates that IGMS has no problem at all paying its short term obligations.
IGMS has a Quick ratio of 5.22. This is comparable to the rest of the industry: IGMS outperforms 57.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.22 | ||
| Quick Ratio | 5.22 |
3. Growth
3.1 Past
IGMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.05%, which is quite impressive.
The Revenue has grown by 57.73% in the past year. This is a very strong growth!
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.88%
Revenue 1Y (TTM)57.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.38%
3.2 Future
The Earnings Per Share is expected to grow by 10.82% on average over the next years. This is quite good.
The Revenue is expected to grow by 88.42% on average over the next years. This is a very strong growth
EPS Next Y30.39%
EPS Next 2Y23.97%
EPS Next 3Y16.86%
EPS Next 5Y10.82%
Revenue Next Year335.62%
Revenue Next 2Y69.89%
Revenue Next 3Y75.55%
Revenue Next 5Y88.42%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
IGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGMS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IGMS's earnings are expected to grow with 16.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.97%
EPS Next 3Y16.86%
5. Dividend
5.1 Amount
IGMS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IGM BIOSCIENCES INC
NASDAQ:IGMS (12/20/2024, 8:18:06 PM)
After market: 6.9 0 (0%)6.9
-0.15 (-2.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners35.9%
Inst Owner Change-3.89%
Ins Owners20.43%
Ins Owner Change5.23%
Market Cap410.27M
Analysts78.75
Price Target19.99 (189.71%)
Short Float %12.44%
Short Ratio12.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-986.91%
Min EPS beat(2)-1950.05%
Max EPS beat(2)-23.77%
EPS beat(4)2
Avg EPS beat(4)-491.9%
Min EPS beat(4)-1950.05%
Max EPS beat(4)4.11%
EPS beat(8)6
Avg EPS beat(8)-242.33%
EPS beat(12)9
Avg EPS beat(12)-163.03%
EPS beat(16)13
Avg EPS beat(16)-120.79%
Revenue beat(2)1
Avg Revenue beat(2)-4.21%
Min Revenue beat(2)-97.74%
Max Revenue beat(2)89.31%
Revenue beat(4)1
Avg Revenue beat(4)-13.34%
Min Revenue beat(4)-97.74%
Max Revenue beat(4)89.31%
Revenue beat(8)2
Avg Revenue beat(8)-23.17%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.03%
PT rev (3m)-14.78%
EPS NQ rev (1m)4.09%
EPS NQ rev (3m)4.09%
EPS NY rev (1m)-5.99%
EPS NY rev (3m)-6.77%
Revenue NQ rev (1m)-10.49%
Revenue NQ rev (3m)-10.49%
Revenue NY rev (1m)22.18%
Revenue NY rev (3m)12.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 140.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.2 | ||
| P/tB | 5.2 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.64
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-2.9
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.05
BVpS1.33
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.2% | ||
| ROE | -278.47% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-52.22%
ROA(5y)-38.61%
ROE(3y)-88.55%
ROE(5y)-60.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 72.08% | ||
| Cap/Sales | 220.73% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.22 | ||
| Quick Ratio | 5.22 | ||
| Altman-Z | -5.04 |
F-Score4
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)204.35%
Cap/Depr(5y)540.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.88%
EPS Next Y30.39%
EPS Next 2Y23.97%
EPS Next 3Y16.86%
EPS Next 5Y10.82%
Revenue 1Y (TTM)57.73%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.38%
Revenue Next Year335.62%
Revenue Next 2Y69.89%
Revenue Next 3Y75.55%
Revenue Next 5Y88.42%
EBIT growth 1Y13.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.95%
EBIT Next 3Y9.23%
EBIT Next 5YN/A
FCF growth 1Y-1274.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4951.28%
OCF growth 3YN/A
OCF growth 5YN/A